[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Indonesia University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":644},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,36,0,25,[9,49,73,100,120,139,161,189,210,246,267,293,320,344,363,386,412,435,457,484,511,538,564,593,625],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100636693","prealbumin-and-igf-1-levels-in-pediatric-chronic-cholestasis-with-severe-malnutrition-after-nutrition-therapy-100636693",false,"NCT07569003","Prealbumin and IGF-1 Levels in Pediatric Chronic Cholestasis With Severe Malnutrition After Nutrition Therapy","Preliminary Study: Effect of Nutrition Therapy on Prealbumin and IGF-1 Level in Severe Malnutrition Under Five Years Old With Chronic Cholestasis","Inclusion Criteria:\n\n* Children under 5 years old\n* Diagnosed with chronic cholestasis and severe malnutrition\n* Parental\u002Fguardian informed consent\n* Willingness to use a nasogastric tube (NGT) if indicated\n* Covered by national health insurance or other insurance\n\nExclusion Criteria:\n\n* Comorbidities (heart failure, chronic kidney disease, HIV)\n* Severe acute infections (acute gastroenteritis, dengue fever, pneumonia)\n* Post-liver transplant\n* Post-Kasai portoenterostomy (jaundice-free)\n* Currently exclusively breastfeeding\n* Use of steroids or NSAIDs within two weeks prior to the study.\n* Receiving a transfusion of whole blood, fresh frozen plasma, or platelets within one week prior to the study","ALL","5 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if a high-energy liquid diet improves the nutritional status of children with chronic cholestasis (a liver condition that blocks bile flow). Researchers want to see if this diet helps children who are malnourished.\n\nThe main questions the study aims to answer are:\n\n* Does the liquid diet raise the level of prealbumin (a marker of nutrition) in the blood?\n* Does the liquid diet raise the level of Insulin-like Growth Factor-1 (IGF-1) (a hormone that helps growth) in the blood?\n\nParticipants will:\n\n* Consume a high-energy liquid diet for 14 days.\n* Give blood samples at the start and at the end of the 2-week study.\n* Keep a daily record of what they eat and drink in a food diary. Researchers will compare the blood test results from the start and the end of the study to see if the liquid diet works to improve the children's prealbumin and IGF-1 levels. This study is important to help children with liver problems grow better and stay healthy.",[27,28,29],"Chronic Cholestasis","Severe Malnutrition","Pediatric Cholestasis",[27,31,32,33,34,35],"Severe malnutrition","Pediatric cholestasis","IGF-1","Prealbumin","Nutrition therapy","RECRUITING","2026-05-01",{"date":39,"type":40},"2026-05-06","ACTUAL",{"date":42,"type":40},"2026-04-06",{"date":44,"type":21},"2026-07",{"name":46,"class":47},"Indonesia University","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":48},"100602111","effectiveness-of-prp-pharmacopuncture-for-chronic-neck-pain-in-cervical-myofascial-syndrome-of-the-upper-trapezius-100602111","NCT07119255","Effectiveness of PRP Pharmacopuncture for Chronic Neck Pain in Cervical Myofascial Syndrome of the Upper Trapezius","The Effectiveness of Pharmacopuncture With Platelet-Rich Plasma (PRP) as a Treatment for Chronic Neck Pain in Cervical Myofascial Syndrome Related to the Upper Trapezius Muscle","Inclusion Criteria:\n\n* Male or female, aged 18 to 59 years.\n* Experiencing neck pain for more than 3 months (chronic).\n* Neck pain classified as Grade I to III according to the Neck Pain Task Force classification.\n* Presence of referred pain pattern on physical examination consistent with the distribution of the upper trapezius muscle.\n* Visual Analogue Scale (VAS) score between 30 and 70 mm (out of 100 mm) during activity (e.g., daily activities or light exercise).\n* Willing to participate in the study until completion and has signed the informed consent form.\n\nExclusion Criteria:\n\n* Hemoglobin level \\\u003C13 g\u002FdL for males or \\\u003C12 g\u002FdL for females.\n* Platelet count \\\u003C150,000\u002FμL.\n* Presence of fever (≥37.5°C).\n* Diagnosis of fibromyalgia.\n* Structural abnormalities of the cervical spine other than degenerative changes, such as fractures, cervical spine injuries, space-occupying lesions (SOL), infections, neoplasms, or systemic diseases confirmed by radiographic imaging.\n* History of cervical spine surgery.\n* Presence of tumors, wounds, or skin infections at the needle insertion site.\n* Diagnosed with blood disorders or currently taking anticoagulant or antiplatelet medications.\n* History of hypersensitivity reactions to acupuncture (e.g., metal allergy, severe atopy, keloids, or other skin hypersensitivities).\n* Uncontrolled cardiovascular disease or diabetes mellitus.\n* History of pharmacopuncture therapy to the upper trapezius muscle within the past 6 months.\n* Use of anti-inflammatory medication within the past 2 weeks.\n* Currently pregnant or breastfeeding.","18 Years","59 Years",{"count":59,"type":21},72,[24],"The goal of this clinical trial is to learn whether pharmacopuncture with Platelet-Rich Plasma (PRP) is effective for treating chronic neck pain in cervical myofascial syndrome related to the upper trapezius muscle. The main questions it aims to answer are:\n\n1. Is pharmacopuncture with Platelet-Rich Plasma (PRP) effective in reducing chronic neck pain in patients with cervical myofascial syndrome related to the upper trapezius muscle?\n2. Does PRP pharmacopuncture improve functional outcomes and quality of life in these patients?\n3. Are there any adverse effects associated with PRP pharmacopuncture in this context?\n\nResearchers will compare PRP pharmacopuncture to normal saline pharmacopuncture (placebo) to evaluate whether PRP provides greater effectiveness in reducing chronic neck pain in cervical myofascial syndrome related to the upper trapezius muscle.\n\nParticipants will:\n\n* Receive a single session of pharmacopuncture therapy\n* Undergo evaluations at week 2, week 4, and week 8 after the intervention",[63,64],"Neck Pain","Myofascial Pain Syndrome","2026-04-13",{"date":67,"type":40},"2026-04-16",{"date":69,"type":40},"2025-09-01",{"date":71,"type":21},"2026-08",{"name":46,"class":47},{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":81,"minAge":56,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":48},"100625261","preoperative-shoulder-exercises-and-postoperative-inflammation-pain-and-function-after-modified-radical-mastectomy-100625261","NCT07420335","Preoperative Shoulder Exercises and Postoperative Inflammation, Pain, and Function After Modified Radical Mastectomy","The Effect of Preoperative Shoulder Range-of-Motion Exercises on C-Reactive Protein (CRP) Levels, Pain, and Shoulder Joint Dysfunction, as Well as Quality of Life in Patients With Locally Advanced Breast Cancer After Modified Radical Mastectomy","Inclusion Criteria:\n\n* Patients with clinically locally advanced breast cancer (stage IIIA-IIIC according to the American Joint Committee on Cancer staging system) who have been scheduled to undergo modified radical mastectomy.\n* Age ≥ 18 years at the time of diagnosis\n* Willing to undergo preoperative rehabilitation for 6-8 weeks and to perform the recommended home-based exercise program.\n* Willing to participate in follow-up via telephone.\n\nExclusion Criteria:\n\n* Inability to understand verbal or written communication, resulting in difficulty following exercise instructions.\n* Intraoperative complications, such as injury to or transection of the thoracodorsal nerve, long thoracic nerve, and\u002For intercostobrachial nerve.\n* Postoperative complications leading to delayed wound healing, defined as incomplete wound healing at one month after surgery, including wound dehiscence, wound infection, or abscess formation.\n* Pre-existing shoulder joint motion limitation diagnosed prior to surgery (e.g., preoperative frozen shoulder).\n* Presence of inflammatory conditions in other body regions at the start of or during the study that may result in elevated leukocyte counts, such as diarrhea, urinary tract infection, or skin infection.\n* Requirement for nonsteroidal anti-inflammatory drugs (NSAIDs) or systemic corticosteroids for the management of inflammation.\n\nDrop out criteria:\n\n* incomplete follow up\n* Unwillingness to undergo repeated blood sampling during the study period.",true,"FEMALE","70 Years",{"count":84,"type":21},52,[24],"This study evaluates whether preoperative shoulder range-of-motion exercises influence postoperative inflammatory response, pain, shoulder function, and quality of life in patients with locally advanced breast cancer undergoing modified radical mastectomy.",[88,89,90],"Locally Advanced Breast Cancer (LABC)","Postoperative Inflammation","Prehabilitation","NOT_YET_RECRUITING","2026-02-12",{"date":94,"type":40},"2026-02-19",{"date":96,"type":21},"2026-01-21",{"date":98,"type":21},"2026-12-03",{"name":46,"class":47},{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":48},"100623320","effectiveness-of-thread-embedding-acupuncture-at-ex-b2-on-the-oswestry-disability-index-and-finger-to-floor-distance-in-chronic-low-back-pain-100623320","NCT07395102","Effectiveness of Thread-Embedding Acupuncture at EX-B2 on the Oswestry Disability Index and Finger-to-Floor Distance in Chronic Low Back Pain","Inclusion Criteria:\n\n* Male or female participants aged ≥ 18 years\n* Participants experiencing low back pain for at least 3 months (\\>12 weeks)\n* Highest low back pain intensity within the past 2 weeks with a score of ≥ 3 on a 0-10 Numeric Pain Rating Scale (NPRS)\n* Receiving pharmacological therapy with a stable analgesic regimen for at least 2 weeks prior to enrollment\n* Presence of physical functional disability as indicated by an Oswestry Disability Index (ODI) score \\> 20%\n* Willing and able to participate in the study until completion and to provide written informed consent\n\nExclusion Criteria:\n\n* History of hypersensitivity reactions to acupuncture or thread embedding acupuncture, or known allergy to stainless steel or polydioxanone (PDO) threads\n* History of keloid formation\n* Presence of scars (cicatrices) or skin disorders at the thread embedding acupuncture insertion sites in the lower back area\n* Specific spinal pathology including fracture, tumor, infection, or severe lumbar spinal stenosis requiring surgical intervention\n* Structural spinal abnormalities (scoliosis or kyphosis) detected on physical examination\n* History of spinal surgery or indication for spinal surgery due to severe neurological deficits\n* Presence of cardiac disease, hematological disorders, or uncontrolled diabetes mellitus\n* Regular use of systemic steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), antiplatelet agents, anticoagulants, or topical analgesic medications\n* Receipt of other treatments for low back pain, including dry needling, neuromuscular taping, spinal injections, or acupuncture within the past 2 weeks, or thread embedding acupuncture within the past 6 months\n* Severe cognitive impairment, severe psychiatric or psychological disorders, or history of alcohol or substance abuse\n* Pregnant or breastfeeding women, or women planning pregnancy within the next 6 months\n* Body mass index (BMI) \\\u003C 18 kg\u002Fm²",{"count":107,"type":21},32,[24],"Chronic low back pain (CLBP) is a leading cause of disability worldwide and significantly impairs functional capacity and quality of life. Non-pharmacological therapies are recommended as first-line management, and acupuncture has demonstrated potential benefits in reducing pain and disability. Thread embedding acupuncture (TEA) is a modified acupuncture technique that provides prolonged stimulation through the implantation of absorbable polydioxanone (PDO) threads at acupuncture points.\n\nThis randomized controlled trial aims to evaluate the effectiveness of TEA at the EX-B2 points compared with sham TEA in improving disability and lumbar flexibility in patients with chronic non-specific low back pain. Disability will be assessed using the Oswestry Disability Index (ODI), and lumbar flexibility will be measured using the Finger-to-Floor Distance (FFD) test over an 8-week follow-up period.",[111],"Chronic Low-back Pain","2026-02-03",{"date":114,"type":40},"2026-02-09",{"date":116,"type":21},"2026-02",{"date":118,"type":21},"2026-05",{"name":46,"class":47},{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":48},"100614337","the-effectiveness-of-press-needle-acupuncture-on-preoperative-anxiety-in-tympanoplasty-and-mastoidectomy-100614337","NCT07278284","The Effectiveness of Press Needle Acupuncture on Preoperative Anxiety in Tympanoplasty and Mastoidectomy","The Effectiveness of Press Needle Acupuncture on Preoperative Anxiety in Tympanoplasty and Mastoidectomy at RSUD Kabupaten Tangerang","Inclusion Criteria:\n\n* Patients diagnosed and scheduled for elective tympanoplasty and mastoidectomy under general anesthesia who experience preoperative anxiety.\n* Patients aged 18-59 years.\n* American Society of Anesthesiologists (ASA) physical status I-II.\n* Patients who have not taken any anti-anxiety medication within the past 24 hours.\n* Willing to participate in the study until completion and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients with a history of psychiatric disorders or those taking psychotropic medications.\n* Presence of contraindications to acupuncture, including medical emergencies, pregnancy, thrombocytopenia with platelet count \\\u003C50,000\u002FµL, and any history of bleeding disorders.\n* Presence of infection, scarring, or malignancy at the acupuncture site.\n* Anatomical abnormalities of the auricle.\n* History of hypersensitivity reactions to prior acupuncture therapy (such as metal allergy, keloids, or other cutaneous hypersensitivity reactions).",{"count":107,"type":21},[24],"The goal of this clinical trial is to learn if press needle acupuncture works to treat preoperative anxiety in Tympanoplasty and Mastoidectomy at RSUD Kabupaten Tangerang in adults. The main questions it aims to answer are:\n\nDoes the press-needle acupuncture administered one day before tympanoplasty and mastoidectomy significantly reduce preoperative anxiety levels-measured using the Amsterdam Preoperative Anxiety and Information Scale (APAIS)-compared with the sham press-needle group at 30 minutes after the intervention and 60 minutes before anesthesia induction?\n\nIs there a difference in effectiveness between press-needle acupuncture and sham press-needle acupuncture in influencing Heart Rate Variability (HRV) among patients undergoing tympanoplasty and mastoidectomy at 30 minutes after the intervention, 60 minutes before anesthesia induction, 2 hours postoperatively, and 24 hours postoperatively?\n\nAre there any adverse events associated with the use of press-needle acupuncture and sham press-needle acupuncture in patients with preoperative anxiety undergoing tympanoplasty and mastoidectomy?\n\nParticipants will:\n\nReceive press-needle acupuncture or sham press-needle acupuncture one day before surgery Have the press needles left in place for a total of 3 days Undergo removal of the needles before hospital discharge Complete preoperative anxiety assessments and routine monitoring according to the study schedule",[131],"Anxiety",{"date":133,"type":40},"2026-02-05",{"date":135,"type":40},"2026-01-18",{"date":137,"type":21},"2026-05-31",{"name":46,"class":47},{"id":140,"slug":4,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":48},"100618866","NCT07337187","Effect of Thread-Embedding Acupuncture at EX-B2 on Pain and Quality of Life in Chronic Low Back Pain","The Effect of Thread-Embedding Acupuncture at EX-B2 Acupoint on Pain Intensity and Quality of Life in Patients With Chronic Low Back Pain","Inclusion Criteria:\n\n* Male or female participants aged ≥18 years\n* Subjects with low back pain lasting for at least 3 months (\\>12 weeks)\n* Maximum low back pain intensity within the past 2 weeks of ≥3 on a 0-10 scale, measured using the Numeric Pain Rating Scale (NPRS) or the Face, Legs, Activity, Cry, Consolability (FLACC) scale\n* Willing to participate in the study until completion and able to provide written informed consent\n* Receiving pharmacological therapy with a stable analgesic regimen for at least the past 2 weeks, which may include non-opioid analgesics (paracetamol), opioid analgesics (codeine, tramadol, morphine), antidepressants (amitriptyline, duloxetine), anticonvulsants (gabapentin, pregabalin, carbamazepine), and\u002For muscle relaxants (eperisone, baclofen)\n\nExclusion Criteria:\n\n* History of hypersensitivity to acupuncture or thread-embedding acupuncture (TEA), including allergy to stainless steel or polydioxanone threads\n* History of keloid formation or skin disorders at the planned TEA insertion sites in the low back area\n* Presence of specific spinal pathology, including fracture, tumor, infection, or severe lumbar spinal stenosis (Schizas grade C or D) requiring surgical intervention\n* Structural spinal abnormalities (scoliosis or kyphosis) detected on physical examination\n* History of spinal surgery or current indication for spinal surgery due to severe neurological deficits\n* Presence of other chronic pain syndromes (fibromyalgia, myofascial pain syndrome, neuropathic pain syndrome, arthritis, chronic pelvic pain, migraine, or chronic tension-type headache) or severe comorbidities (stroke with sensory deficits, Parkinson's disease, end-stage chronic kidney disease, or terminal heart failure) that may affect pain assessment\n* Presence of cardiac disease, hematologic disorders, or uncontrolled diabetes mellitus\n* Regular use of systemic steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), antiplatelet agents, anticoagulants, or topical analgesics\n* Body mass index (BMI) \\\u003C18 kg\u002Fm²\n* Receive other therapies for low back pain, including dry needling, neuromuscular taping, or acupuncture within the past 2 weeks, or thread-embedding acupuncture within the past 6 months\n* Receive spinal interventional therapy (surgery or injection) within the past 3 months, or stem cell therapy for chronic low back pain within the past 12 months\n* Cognitive impairment or other neurological disorders, severe psychiatric or psychological conditions, or a history of alcohol or substance abuse\n* Pregnant or breastfeeding women, or women planning to become pregnant within the next 6 months",{"count":107,"type":21},[24],"The goal of this clinical trial is to learn whether thread-embedding acupuncture (TEA) is more effective than sham thread-embedding acupuncture in treating adults with chronic low back pain. The study will also evaluate the safety of TEA.\n\nThe main questions it aims to answer are:\n\n* Does TEA reduce pain intensity more effectively than sham TEA?\n* Does TEA improve quality of life compared with sham TEA?\n* Does TEA reduce the frequency of bothersome pain episodes?\n* Does TEA reduce the use of routine and additional (extra) pain medications?\n* What side effects occur in participants receiving TEA compared with sham TEA?\n\nResearchers will compare TEA with sham TEA (a procedure that mimics acupuncture without needle insertion or thread placement) to determine whether TEA provides greater and longer-lasting benefits for chronic low back pain.\n\nParticipants will:\n\n* Receive a single session of TEA or sham TEA\n* Continue using pain medications as prescribed by their physician\n* Be evaluated at weeks 2, 4, 6, and 8 after treatment\n* Complete pain assessments, quality-of-life questionnaires, and reports of pain episodes and medication use\n* Attend in-person clinic visits at weeks 4 and 8, and receive telephone follow-ups at weeks 2 and 6",[149],"Low Back Pain",[151,152],"Chronic Low Back Pain","Lumbago","2026-01-06",{"date":155,"type":40},"2026-01-13",{"date":157,"type":21},"2026-01-01",{"date":159,"type":21},"2026-06-30",{"name":46,"class":47},{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":48},"100616303","effectiveness-of-goal-directed-fluid-therapy-guided-by-cardiac-index-versus-central-venous-pressure-in-major-abdominal-surgery-patients-in-the-icu-100616303","NCT07303855","Effectiveness of Goal-Directed Fluid Therapy Guided by Cardiac Index Versus Central Venous Pressure in Major Abdominal Surgery Patients in the ICU.","Inclusion Criteria:\n\n* Adult patients aged 18 to 65 years.\n* Patients with a Body Mass Index (BMI) between 18 and 30 kg\u002Fm².\n* Patients undergoing elective major abdominal surgery with a planned postoperative admission to the ICU.\n* Patients with an American Society of Anesthesiologists (ASA) physical status classification of I to III.\n\nExclusion Criteria:\n\n* Patients with pre-operative cardiovascular disorders (Coronary Artery Disease, or heart failure NYHA Class III and IV).\n* Patients with severe renal impairment (Chronic Kidney Disease Stage V) with or without hemodialysis and fluid restrictions.\n* Non-sinus cardiac rhythm.\n* Pregnancy.\n* Patients with right heart failure (patients with signs of congestion and symptoms of right heart failure accompanied by evidence of reduced right ventricular function, indicated by TAPSE \\\u003C 17 mm).\n* Patients with pulmonary hypertension (patients with echocardiographic suspicion of tricuspid regurgitation, tricuspid regurgitation velocity \\> 3.4 m\u002Fs, or mean pulmonary artery pressure \\> 20 mmHg from right heart catheterization).\n* Patients with Acute Respiratory Distress Syndrome (ARDS) or patients requiring specialized ventilation modes.\n* Patients who refuse to participate in the study.","65 Years",{"count":169,"type":21},60,[24],"This study aims to compare two different methods for guiding intravenous (IV) fluid therapy in patients during their first 6 hours in the ICU after major abdominal surgery. The goal is to determine which method leads to a more optimal and precise amount of fluid administration. The objective is to compare the total fluid volumes administered when guided by Cardiac Index versus Central Venous Pressure, as well as mortality, length of stay, relaparotomy and reintubation in order to identify the more precise fluid management strategy for postoperative ICU patients.",[173],"Elective Major Abdominal Surgery",[175,176,177,178,179,180],"cardiac index","central venous pressure","goal-directed fluid therapy","elective major abdominal surgery","postoperative fluid management","intensive care","2025-12-24",{"date":183,"type":40},"2025-12-29",{"date":185,"type":40},"2025-12-01",{"date":187,"type":21},"2026-02-28",{"name":46,"class":47},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":17,"minAge":196,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":209,"locationsCount":48},"100613794","safety-and-efficacy-of-ear-acupuncture-for-antituberculosis-drug-related-nausea-and-vomiting-100613794","NCT07271225","Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting","Effectiveness and Safety of Auricular Acupuncture for Nausea and Vomiting Side Effects Induced by Anti-Tuberculosis Drugs in Pulmonary TB Patients","Inclusion Criteria:\n\n* Participants are individuals diagnosed with drug-sensitive tuberculosis or drug-resistant tuberculosis receiving short-term treatment regimens (BPaL\u002FBPaLM)\n* Participants are aged 17 years or older.\n* Participants experience nausea and vomiting after taking antituberculosis drugs.\n* Participants are willing to comply with the study schedule until completion and provide written informed consent.\n\nExclusion Criteria:\n\n* Presence of skin lesions at the site where press needles (PN) will be applied\n* Participants who experience nausea and vomiting prior to antituberculosis treatment (including comorbidities that may cause nausea and vomiting, such as renal failure and liver disorders)\n* Participants with drug-resistant tuberculosis (DR-TB) receiving long-term or individualized treatment regimens\n* Participants with diabetes mellitus and a random blood glucose level \\> 200 mg\u002FdL\n* Participants with unstable hemodynamic status\n* Participants who have received acupuncture therapy within the last 2 weeks\n* Participants with coagulation disorders (platelet count \\\u003C 50,000\u002FµL)\n* Participants with a history of hypersensitivity reactions to previous acupuncture treatment","17 Years",{"count":198,"type":21},58,[24],"This study will look at whether press-needle ear acupuncture can help lower nausea and vomiting caused by antituberculosis medicines in people with pulmonary tuberculosis. Nausea and vomiting are common side effects of tuberculosis treatment, and they can make people stop taking their medicines\n\nWhen treatment is stopped too early, tuberculosis may not be cured and may become resistant to medicines.\n\nParticipants in this study will have nausea and vomiting related to their tuberculosis treatment. They will be randomly assigned to one of two groups. One group will receive press-needle ear acupuncture. The other group will receive a placebo version that looks similar but does not stimulate acupuncture points\n\nResearchers will check nausea and vomiting scores before treatment, during treatment, and after treatment to see whether press-needle acupuncture works better than placebo and whether it is safe. Press-needle acupuncture may help reduce nausea and vomiting by affecting nerves and lowering certain chemicals that trigger these symptoms, and it has minimal side effects\n\nIf this method is proven helpful and safe, it may give patients a comfortable and low-risk way to manage nausea and vomiting during tuberculosis treatment",[202],"Tuberculosis, Pulmonary","2025-11-27",{"date":205,"type":40},"2025-12-09",{"date":207,"type":40},"2025-11-05",{"date":159,"type":21},{"name":46,"class":47},{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":80,"sex":81,"minAge":218,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":222,"phases":4,"briefSummary":223,"conditions":224,"keywords":230,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":48},"100606081","dietary-patterns-inflammation-zinc-status-and-body-composition-in-multi-ethnic-women-of-reproductive-age-in-jakarta-100606081","NCT07170904","Dietary Patterns, Inflammation, Zinc Status, and Body Composition in Multi-Ethnic Women of Reproductive Age in Jakarta","The Relationship Between Dietary Patterns and Hair Zinc Levels With Body Composition, TNF-α, and Blood Pressure in Women of Reproductive Age (WRA) With Multi-Ethnicities in Jakarta: A Cross-Sectional Study","DIVERSE","Inclusion Criteria:\n\n* Women aged 19-49 years\n* Residing in Jakarta for at least 6 months\n* Currently menstruating (not menopausal)\n* From Minangkabau, Sundanese, Javanese, Betawi, or Chinese ethnicity\n* Not pregnant or breastfeeding at the time of study\n\nExclusion Criteria:\n\n* History of chronic diseases (e.g., diabetes, cardiovascular disease, cancer)\n* Currently on a medically prescribed diet or taking medication affecting nutrient status\n* Any condition interfering with accurate body composition measurement","19 Years","49 Years",{"count":221,"type":21},188,"OBSERVATIONAL","This study aims to determine the relationship between dietary patterns and hair zinc levels with body composition, tumor necrosis factor alpha (TNF-α), and blood pressure in women of reproductive age from different ethnic backgrounds in Jakarta, Indonesia (specifically Minangkabau, Sundanese, Javanese, Betawi, and Chinese). Participants are assessed once through dietary assessment, anthropometric measurements, and biological sample collection.",[225,226,227,228,229],"Body Composition","Zinc Status","Dietary Analysis","TNF Alpha","Blood Pressure",[231,232,233,234,235,236,237],"women of reproductive age","dietary assessment","hair zinc","TNF alpha","body composition","blood pressure","BOD POD","2025-11-26",{"date":240,"type":40},"2025-12-04",{"date":242,"type":40},"2025-02-03",{"date":244,"type":21},"2026-03-31",{"name":46,"class":47},{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":48},"100609110","press-needle-on-body-acupuncture-points-and-auricular-acupuncture-points-on-functional-dyspepsia-100609110","NCT07210294","Press Needle on Body Acupuncture Points and Auricular Acupuncture Points on Functional Dyspepsia","The Effect of Press Needle on Body Acupuncture Points and Auricular Acupuncture Points on Functional Dyspepsia","Inclusion Criteria:\n\n* Male or female aged 18-59 years\n* Patients with functional dyspepsia\n* Esophagogastroduodenoscopy (EGD) results show no significant structural abnormalities or no structural abnormalities.\n* Willing to participate in the research until completion and sign a letter of consent for medical action (informed consent).\n\nExclusion Criteria:\n\n* At the acupuncture point location there is inflammation, malignancy, and scar tissue.\n* Deformity of the earlobe.\n* History of allergies to stainless steel and plaster.\n* Medical emergencies, impaired consciousness, pregnancy, history of diabetes mellitus, and history of keloid formation.\n* History of digestive tract cancer, history of hepatobiliary cancer, history of chronic kidney failure stage 4 and 5, history of hyperthyroidism or hypothyroidism.",{"count":254,"type":21},38,[24],"The aim of this study was to prove that press needle (PN) and medication are more effective in reducing symptoms and improving quality of life in people with functional dyspepsia compared to sham press needle (Sham PN) and medication.\n\nThe main questions this study aims to answer are:\n\n* Does the press needle and medication group reduce symptoms in people with functional dyspepsia as assessed by the Short Form-Leeds Dyspepsia Questionnaire (SF-LDQ) compared to the sham press-needle and medication group on days 7 and 14, compared to before therapy?\n* Does the press-needle and medication group improve quality of life in people with functional dyspepsia as assessed by the Short-Form Nepean Dyspepsia Index (SF-NDI) compared to the sham press-needle and medication group on days 7 and 14, compared to before therapy?\n\nA total of 38 participants were randomly allocated into two groups, either PN or Sham PN needle groups\n\nParticipants will:\n\n* Receive PN or Sham PN for 14 days and replaced on day 7.\n* Complete the SF-LDQ and SF-NDI questionnaires before therapy, on day 7, and day 14.",[258],"Functional Dyspepsia","2025-09-29",{"date":261,"type":40},"2025-10-07",{"date":263,"type":40},"2025-08-28",{"date":265,"type":21},"2026-07-06",{"name":46,"class":47},{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":48},"100607011","development-of-a-dietary-intervention-model-based-on-genetic-data-as-an-implementation-of-a-healthy-lifestyle-in-the-management-of-systemic-lupus-erythematosus-patients-100607011","NCT07183007","Development of a Dietary Intervention Model Based on Genetic Data as an Implementation of a Healthy Lifestyle in the Management of Systemic Lupus Erythematosus Patients","Inclusion Criteria:\n\n1. Patients with systemic lupus erythematosus (SLE) diagnosed according to the 2019 EULAR\u002FACR criteria, registered as patients at RSCM.\n2. Age above 18 years\n\nExclusion Criteria:\n\n1. Presence of active infection.\n2. Refusal to participate in the study.\n3. Pregnancy.\n4. Breastfeeding.\n5. Already on a specific autoimmune-related diet.\n6. Patients with severe medical conditions (active cancer, stage V chronic kidney disease, or acute heart failure).\n7. Patients taking corticosteroids equivalent to more than 20 mg\u002FdL prednisone",{"count":274,"type":21},100,[24],"The goal of this clinical trial is to learn if dietary intervention based on genetic data benefits in the management of systemic lupus erythematosus patients. It will also learn about the safety of this intervention. The main questions it aims to answer are:\n\n* What is the effect of dietary intervention based on genetic data as part of a healthy lifestyle in the management of SLE patients on disease activity?\n* What is the effect of dietary intervention based on genetic data as part of a healthy lifestyle in the management of SLE patients on quality of life Researchers would compare dietary intervention based on genetic data to a no intervention to see if dietary intervention based on genetic data improves disease activity and quality of life of SLE patients.\n\nParticipants will:\n\n* Be checked for genetic test (HLA DQ2 and DQ8) as screening\n* Be randomized to dietary intervention group or control group if has HLA DQ2 or DQ8 positive from screening\n* Visit the clinic once every month for checkups and lab test if were randomized to dietary intervention group or control group\n* Do food record as instructed if were randomized to dietary intervention group or control group",[278],"Systemic Lupus Erythematosus",[280,281,282,283,284],"systemic lupus erythematosus","dietary intervention","nutrigenomic","HLA-DQ2","HLA-DQ8","2025-09-13",{"date":287,"type":40},"2025-09-19",{"date":289,"type":21},"2025-09-21",{"date":291,"type":21},"2026-03",{"name":46,"class":47},{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":17,"minAge":299,"maxAge":167,"enrollmentInfo":300,"targetDuration":4,"studyType":22,"phases":302,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":317,"leadSponsor":319,"locationsCount":48},"100604032","phase-2-mesenchymal-stromalstem-cells-derived-exosomes-msc-exos-therapy-for-type-2-diabetes-mellitus-patients-100604032","NCT07144241","Mesenchymal Stromal\u002FStem Cells-Derived Exosomes (MSC-Exos) Therapy for Type 2 Diabetes Mellitus Patients","Inclusion Criteria:\n\n* Patients diagnosed with Type 2 Diabetes Mellitus.\n* Patients aged 40 to 65 years.\n* Patients who are willing to participate in the study and sign the informed consent form after receiving a detailed explanation of the research procedure.\n\nExclusion Criteria:\n\n* Patients with severe comorbidities that could affect the immune response, such as autoimmune diseases, malignancies, and severe infections.\n* Patients currently undergoing anticoagulant therapy.\n* Patients currently undergoing immunosuppressive therapy.\n* Pregnant women, as the effects of exosome therapy on them have not been sufficiently studied.\n* Patients with a history of severe allergies to components of the exosome therapy.\n* Patients with CKD (Chronic Kidney Disease) on HD (Hemodialysis).","40 Years",{"count":301,"type":21},50,[303],"PHASE2","This is an open-label randomized controlled trial with a pre-and-post-test control group design to evaluate the effect of Mesenchymal Stromal\u002FStem Cells-Derived Exosomes (MSC-Exos) as an adjunctive therapy on glycemic control and clinical outcomes in patients with Type 2 Diabetes Mellitus (T2DM). The study aims to determine if the addition of exosome therapy to standard care can improve glycemic parameters (fasting blood glucose, 2-hour postprandial glucose, HbA1c, and C-peptide), quality of life, and inflammatory biomarkers (IL-6, IL-10, D-dimer, and CRP). The study will involve 50 subjects, randomly allocated into two groups: an intervention group and a control group. The intervention group will receive standard T2DM therapy plus a combination of exosomes (1 vial Exo-HWS + 1 vial Exo-HUVEC). The control group will receive standard T2DM therapy plus 1 vial Exo-HWS. The study duration is from June to December 2025.",[306],"Type 2 Diabetes Mellitus",[308,309,310,311,312],"DMT2","Mesenchymal Stromal\u002FStem Cells-Derived Exosomes","Glycemic Profile","Quality of Life","Inflammatory Biomarkers","2025-08-20",{"date":315,"type":40},"2025-08-27",{"date":69,"type":21},{"date":318,"type":21},"2026-07-01",{"name":46,"class":47},{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":80,"sex":81,"minAge":328,"maxAge":329,"enrollmentInfo":330,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":48},"100603485","secretome-tgf-beta-3-100603485","NCT07137130","Secretome TGF Beta 3","Development Of Adipose-Derived Mesenchymal Stem Cells Secretome (ADMSCS) Based Products From Stem Cell Conditioned Medium For Melasma Therapy","TGF Beta 3","Inclusion Criteria:\n\n* Women diagnosed with melasma.\n* Women without melasma and have areas of skin that are clinically free of lesions for SP control.\n* 30-60 years old.\n* Fitzpatrick skin type IV-V.\n* Willing to be a research subject by signing a research consent form (Informed Consent).\n\nExclusion Criteria:\n\n* Pregnant and breastfeeding women.\n* Currently using hormonal contraception or have ever used contraception hormones in the last 6 months.\n* Using topical therapy for melasma, for example corticosteroids, tretinoin, hydroquinone, and other therapies that whiten or brighten the skin in the last 2 weeks.\n* Using topical triple combination cream therapy for at least 3 months and did not show significant improvement\n* Using systemic therapy for melasma, for example antioxidants or tranexamic acid in the last 4 weeks.\n* History of superficial peeling therapy in the last 4 weeks.\n* History of deep peeling therapy, laser or mechanical abrasion in the last 6 months.\n* Using drugs that are photosensitizers such as tetracycline, phenytoin, carbamazepine, spironolactone.\n* History of blood clotting disorders or on blood thinning therapy.\n* Allergy to tranexamic acid.\n* Have other skin complaints that may interfere with the evaluation of melasma, for example post-inflammatory hyperpigmentation, Hori's nevus, Ota's nevus, pigmented contact dermatitis, and other pigmentation disorders\n* Difficulty complying with treatment.","30 Years","60 Years",{"count":331,"type":21},34,[24],"A therapeutic modality currently being developed for melasma is secretome. Secretome is a bioactive molecule secreted by mesenchymal stem cells in a conditioned medium containing a large number of growth factors, cytokines, various macromolecules, and extracellular vesicles, including microvesicles and exosomes, that can stimulate various biological reactions, particularly in modulating new tissue formation. Secretome can provide a depigmenting effect by increasing the proliferation and migration of epidermal keratinocytes, which contain melanin pigment, in line with increased fibroblast synthesis.\n\nSecretomes contain various cytokines and growth factors, one of which is transforming growth factor (TGF)-β. TGF-β is primarily secreted by fibroblasts (FB) and, to a lesser extent, by keratinocytes, and plays a crucial role in regulating melanocyte function. TGF-β has been reported to inhibit cAMP\u002Fprotein kinase A signaling and induce GLI2, which then suppresses microphthalmia-associated transcription factor (MITF), a central transcription factor in melanogenesis. A study by Moon et al. in Korea examined TGF-β3. Moon et al. examined the effects of TGF-β3 on melanogenesis in human melanocytes co-cultured with skin cells irradiated with ultraviolet (UV) light, and in UV-irradiated human skin. The results showed that UVB irradiation or stem cell factor (SCF)\u002Fendothelin-1 (ET-1) increased melanogenesis. TGF-β3 effectively inhibited melanin accumulation and tyrosinase activity by downregulating the extracellular signal-regulated kinase (ERK)\u002Fmicrophthalmia-associated transcription factor (MITF) pathway. TGF-β3 increased the expression of keratinocyte differentiation markers.\n\nMechanistically, TGF-β3 inhibits melanogenesis by inhibiting MITF expression, which is regulated by ERK. TGF-β1 reduces MITF but at the risk of inducing skin fibrosis. However, in the study by Moon et al., the aforementioned TGF Beta 1 function was not found in TGF-β3. Furthermore, TGF-β3 restored skin differentiation function in UV-irradiated keratinocytes.\n\nTo date, there have been no clinical trials comparing intradermal injection of concentrated secretome with intradermal injection of concentrated secretome with the addition of TGF-β3 as a melasma therapy in Indonesia, thus encouraging researchers to conduct further research.",[335],"Melasma","2025-08-15",{"date":338,"type":40},"2025-08-22",{"date":340,"type":21},"2026-02-14",{"date":342,"type":21},"2026-12-20",{"name":46,"class":47},{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":22,"phases":352,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":362,"locationsCount":48},"100601627","press-needle-acupuncture-for-pain-and-quality-of-life-in-lung-cancer-patients-100601627","NCT07112950","Press Needle Acupuncture for Pain and Quality of Life in Lung Cancer Patients","The Effect of Press Needle Acupuncture on Pain Reduction and Quality of Life Improvement in Lung Cancer Patients","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of lung cancer through histopathology or radiology.\n* Lung cancer patients aged over 18 years.\n* Stage III-IV lung cancer patients receiving therapy at Dr. Cipto Mangunkusumo National General Hospital (RSUPN) and Tangerang District General Hospital (RSUD Kabupaten Tangerang).\n* Patients with a VAS score \\>10 mm for baseline pain and \\>40 mm during breakthrough pain.\n* Willing to participate in the study until completion by signing the informed consent form.\n\nExclusion Criteria:\n\n* Lung cancer patients with deteriorating general condition.\n* Presence of wounds or infections at the press needle insertion site.\n* History of allergy to stainless steel materials.\n* Patients with blood clotting disorders: platelet count \\\u003C50,000\u002FμL, ANC \\\u003C1000\u002Fmm³, or patients undergoing anticoagulant therapy with INR \\>2.142.",{"count":107,"type":21},[24],"The purpose of this clinical trial is to evaluate the effect of press needle acupuncture on pain management and quality of life improvement in patients with lung cancer.\n\nThe main question this study aims to answer is:\n\nDoes press needle acupuncture, when combined with standard therapy, provide better pain relief and quality of life improvement in lung cancer patients compared to standard therapy alone?\n\nResearchers will compare press needle acupuncture to sham acupuncture to determine whether press needle acupuncture is more effective in reducing pain and improving quality of life.\n\nParticipants will:\n\nReceive either press needle acupuncture or sham press needle acupuncture for 7 days\n\nVisit the clinic once a week for examination and evaluation\n\nRecord improvements in pain intensity in a pain diary and assess quality of life using a quality of life questionnaire",[355],"Lung Cancer Patients","2025-08-01",{"date":358,"type":40},"2025-08-08",{"date":360,"type":21},"2025-08-11",{"date":185,"type":21},{"name":46,"class":47},{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":56,"enrollmentInfo":370,"targetDuration":4,"studyType":22,"phases":372,"briefSummary":367,"conditions":373,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":48},"100597530","high-flow-nasal-cannula-vs-niv-after-extubation-in-children-undergoing-heart-surgery-100597530","NCT07059689","High-Flow Nasal Cannula vs. NIV After Extubation in Children Undergoing Heart Surgery","High Flow Nasal Cannula vs. Non-Invasive Ventilation in Post-Extubation Pediatric Cardiac Surgery Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients under 18 years of age.\n* Post-cardiac surgery patients in the CICU of Cipto Mangunkusumo National General Hospital\n* Patients at high risk of extubation failure (e.g., young age, open sternotomy, mechanical ventilation \\>48 hours).\n* Patients who pass the extubation readiness test and spontaneous breathing trial.\n\nExclusion Criteria:\n\n* Diaphragmatic paralysis.\n* Decreased consciousness.\n* Neuromuscular disease.\n* Pneumothorax without drainage.\n* Airway obstruction.\n* Patients with a tracheostomy.\n* Unplanned extubation.\n* Patient received PEEP (Positive End-Expiratory Pressure) \\>7 prior to extubation",{"count":371,"type":21},114,[24],[374,375,376,377],"Heart Defects, Congenital","Intensive Care Units, Pediatric","Respiration, Artificial","Extubation","2025-07-07",{"date":380,"type":40},"2025-07-11",{"date":382,"type":40},"2025-06-05",{"date":384,"type":21},"2025-12",{"name":46,"class":47},{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":17,"minAge":329,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":22,"phases":393,"briefSummary":394,"conditions":395,"keywords":400,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":48},"100596745","the-effect-of-swallowing-exercise-and-maneuver-program-for-older-adults-with-dysphagia-in-nursing-home-100596745","NCT07049471","The Effect of Swallowing Exercise and Maneuver Program For Older Adults With Dysphagia in Nursing Home","Inclusion Criteria:\n\n* aged 60 years or older\n* experiencing swallowing difficulties as assessed by the Eating Assessment Tool-10 (EAT-10)\n* having no history of neurological disease\n* possessing adequate communication abilities\n* and being capable of performing daily activities either independently or with partial assistance\n\nExclusion Criteria:\n\n* individuals with dermatological conditions in the anterior neck region, hypertension, orofacial pain such as trigeminal neuropathy or toothache, as well as those with significant malocclusion or facial asymmetry",{"count":59,"type":21},[24],"This clinical trial aimed to evaluate the effectiveness of a structured swallowing exercise and maneuver program for older adults with dysphagia living in a nursing home. Dysphagia, or difficulty in swallowing, is common in elderly populations and may lead to malnutrition, dehydration, and aspiration pneumonia.\n\nIn this study, 72 participants aged 60 years and older were randomly assigned to either an intervention group or a control group. The intervention group received a combined swallowing exercise and maneuver program-including Masako Maneuver, Chin Tuck Against Resistance, Supraglottic Swallow, and Super-Supraglottic Swallow-performed three times daily before meals over a six-week period. The control group received standard care, including upright sitting posture during meals.\n\nSwallowing ability was measured using the EAT-10 questionnaire. The intervention group showed significant improvement in swallowing scores, while no meaningful changes were observed in the control group. This study suggests that nurse-led swallowing exercises can be a safe, simple, and effective strategy to improve swallowing function and quality of life in older adults living in long-term care settings.",[396,397,398,399],"Oropharyngeal Dysphagia","Swallowing Disorders","Frailty-related Dysphagia","Nursing Homes",[396,401,402,403],"older adult","nursing home","swallowing","2025-06-25",{"date":406,"type":40},"2025-07-03",{"date":408,"type":21},"2025-07-10",{"date":410,"type":21},"2025-08-31",{"name":46,"class":47},{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":80,"sex":17,"minAge":56,"maxAge":167,"enrollmentInfo":419,"targetDuration":4,"studyType":22,"phases":420,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":48},"100595864","the-effect-of-quadratus-lumborum-ql-block-on-the-incidence-of-chronic-neuropathic-pain-after-retroperitoneal-laparoscopic-donor-nephrectomy-a-study-on-neuroinflammation-and-neurophysiology-100595864","NCT07037992","The Effect of Quadratus Lumborum (QL) Block on the Incidence of Chronic Neuropathic Pain After Retroperitoneal Laparoscopic Donor Nephrectomy: A Study on Neuroinflammation and Neurophysiology","The Effect of Subcostal Anterior Quadratus Lumborum Block on the Incidence of Chronic Neuropathic Pain After Retroperitoneal Laparoscopic Donor Nephrectomy: A Study on Neuroinflammation and Neurophysiology","Inclusion Criteria:\n\nLiving kidney donor candidate patients aged 18-65 years Patients with ASA physical status assessment 1-3 Patients are willing to be research subjects.\n\nExclusion Criteria:\n\n* The patient was known to have a history of chronic non-cancer pain and cancer pain.\n\nThe patient had a history of preoperative laparoscopic kidney donor surgery.",{"count":169,"type":21},[24],"To analyze the relationship of anterior subcostal quadratus lumborum (QL) block compared with control block on the incidence of chronic neuropathic pain at three months post-laparoscopic retroperitoneal living kidney donor.",[423,424,425,426],"Chronic Pain","Living Kidney Donor","Quadratus Lumborum Block","Laparoscopic Donor Nephrectomy","2025-06-17",{"date":429,"type":40},"2025-06-26",{"date":431,"type":21},"2025-07-01",{"date":433,"type":21},"2025-12-31",{"name":46,"class":47},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":167,"enrollmentInfo":441,"targetDuration":4,"studyType":22,"phases":443,"briefSummary":444,"conditions":445,"keywords":447,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":456},"100594761","comparison-of-clinical-outcomes-between-all-inside-and-complete-tibial-tunnel-techniques-in-anterior-cruciate-ligament-reconstruction-among-patients-with-acl-ruptures-100594761","NCT07023653","Comparison of Clinical Outcomes Between All-Inside and Complete Tibial Tunnel Techniques in Anterior Cruciate Ligament Reconstruction Among Patients With ACL Ruptures","Inclusion Criteria:\n\n* Patients with anterior cruciate ligament rupture\n* Patients within the age range of 18 to 65 years\n\nExclusion Criteria:\n\n* Patients with Multiple Ligament Injuries in the Knee Joint\n* Patients with a pregnancy condition\n* Patients with Severe Osteochondral Defect (ICRS 4)\n* Patients with signs of inflamation in knee joint",{"count":442,"type":21},40,[24],"This study aims to compare the functional outcomes of patients with ACL rupture following ACL reconstruction surgery using hamstring grafts, between the all-inside technique and the complete tibial tunnel technique. The hamstring graft, which serves as the tissue substitute for the damaged ACL, is harvested from the posterior thigh of the patient and used to replace the torn ligament during reconstruction",[446],"Anterior Cruciate Ligament Rupture",[448],"All-inside Techniques","2025-06-09",{"date":427,"type":40},{"date":452,"type":40},"2024-10-15",{"date":454,"type":21},"2026-12-01",{"name":46,"class":47},2,{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":80,"sex":465,"minAge":56,"maxAge":328,"enrollmentInfo":466,"targetDuration":4,"studyType":22,"phases":467,"briefSummary":468,"conditions":469,"keywords":471,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":48},"100593583","comparing-hict-and-mict-for-health-improvements-in-overweight-young-adults-100593583","NCT07008326","Comparing HICT and MICT for Health Improvements in Overweight Young Adults","Comparative Effects of High-Intensity Circuit Training and Moderate-Intensity Continuous Training on Various Health Parameters in Overweight Young Adults","HiMod Impact","Inclusion Criteria:\n\n* Overweight (BMI 23-24.9 kg\u002Fm2)\n* Physically inactive in the last 6 months before the study (\\\u003C150 minutes of moderate-intensity activity and \\\u003C75 minutes of high-intensity activity)\n* Willing to participate in exercise program for 12 weeks\n* No other exercise program during the study period\n\nExclusion Criteria:\n\n* Smoking\n* Medical comorbidities (diabetes mellitus, hypertension, cardiovascular disease, asthma, dyslipidaemia, epilepsy)\n* History of musculoskeletal injuries or health problems related to exercise in the last 1 year\n\nDropout Criteria\n\n* Resigning\n* Not participating in the endline assessment\n* Not participating in the exercise program for 2 consecutive weeks\n* Experiencing injury or health problems that led to the inability to participate in the program for 2 consecutive weeks","MALE",{"count":5,"type":21},[24],"The increasing prevalence of overweight and obesity is becoming a concern worldwide as it is associated with the increased prevalence of non-communicable diseases. One of the main reasons for this problem is that more adults did not fulfill the weekly physical activity recommendations, with the lack of time and motivation as the main factor. This study aims to compare the effectiveness of a high-intensity circuit training program and the more familiar moderate-intensity continuous training in improving body composition, cardiorespiratory fitness, lipid profile, oxidative stress, and inflammatory markers in young adult males. At the same time, it also explores its adherence through its enjoyment scale and gradual changes in supervision. This experimental study compares pre- and post-tests in the two groups. 3-days food records and 7-days physical activity will be measured monthly as the confounding factors.",[470],"Overweight",[472,473,474,475],"high intensity circuit training","moderate intensity continuous training","overweight","young adult male","2025-06-04",{"date":478,"type":40},"2025-06-06",{"date":480,"type":21},"2025-06-01",{"date":482,"type":21},"2025-09-30",{"name":46,"class":47},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":17,"minAge":491,"maxAge":492,"enrollmentInfo":493,"targetDuration":4,"studyType":22,"phases":495,"briefSummary":496,"conditions":497,"keywords":499,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":510,"locationsCount":456},"100587859","effects-of-channa-striata-extract-on-intestinal-inflammation-and-nutritional-status-in-malnutritional-toddlers-after-albendazole-therapy-in-south-bangka-district-100587859","NCT06933862","Effects of Channa Striata Extract on Intestinal Inflammation and Nutritional Status in Malnutritional Toddlers After Albendazole Therapy in South Bangka District","Striatin1","Inclusion Criteria:\n\n* Malnourished children aged 1.5-5 years (-3SD to \\\u003C -2 SD)\n* Parents or guardians are willing to participate in the study\n* Parents or guardians can read and fill out the questionnaire\n\nExclusion Criteria:\n\n* Children with chronic diseases such as tuberculosis, congenital heart disease, diabetes, cancer, epilepsy, HIV Aids, sickle cell anemia, and mental illness.\n* Children with history of snakehead fish allergy\n* Children with physical disabilities that complicate data collection","17 Months","60 Months",{"count":494,"type":21},122,[24],"The goal of this clinical trial is to learn if intervention with channa striata extract or inbumin forte sachet as a food supplement can improve intestinal damage and nutritional status in malnourished children aged 1.5-5 years. The main questions it aims to answer are:\n\n* Whether there is a change in calprotectin and AAT levels after administration of snakehead fish extract of inbumin forte sachet?\n* Whether there is a difference in changes in nutritional status after administration of snakehead fish extract or inbumin forte sachet? Researchers will compare snakehead fish extract or inbumin forte sachet to a placebo (a look-alike substance that contains no drug) to see if snakehead fish extract or inbumin forte sachet works to treat children malnutrition.\n\nParticipants will take snakehead fish extract or inbumin forte sachet or placebo every day for 3 months. Researchers will visit study participants every month to check their weight and height and monitor vitamin administration through photos, notes and videos sent every day and records complaints or symptoms that may arise and at the end of 3 months, researchers will collect stool and blood samples and check nutritional status.",[498],"Malnourished Children",[500,501,502,503],"snakehead fish extract","malnourished children","Calprotectin","striatin","2025-04-10",{"date":506,"type":40},"2025-04-18",{"date":508,"type":21},"2025-05-15",{"date":159,"type":21},{"name":46,"class":47},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":17,"minAge":518,"maxAge":57,"enrollmentInfo":519,"targetDuration":4,"studyType":22,"phases":521,"briefSummary":523,"conditions":524,"keywords":526,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":48},"100585529","phase-4-the-effect-of-propolis-administration-on-cholesterol-level-in-diabetic-type-2-patients-100585529","NCT06903546","The Effect of Propolis Administration on Cholesterol Level in Diabetic Type 2 Patients","The Effect of Propolis Administration on Low Density Lipoprotein and High Density Lipoprotein in Diabetic Type 2 Patients in Central Jakarta","Inclusion Criteria:\n\n* Controlled Diabetes Mellitus type 2 with HbA1c \\\u003C7.5%\n* BMI 23-35 kg\u002Fm2\n* On anti-cholesterol therapy\n\nExclusion Criteria:\n\n* Using injection therapy (insulin or GLP-1 RA)\n* History of bees product allergy\n* Active smoker\n* Consuming alcohol\n* Altered liver (ALT\\>35 IU\u002FL) and kidney (eGFR\\\u003C90 mL\u002Fmin) function\n* Pregnant and breastfeeding women\n* History of cardiovascular disease (heart attack, stroke)","35 Years",{"count":520,"type":21},64,[522],"PHASE4","The goal of this clinical trial is to learn if propolis administration works to change the level of Low Density Lipoprotein (LDL) and High Density Lipoprotein cholesterol (HDL) in diabetic type 2 patients.\n\nThe main questions it aims to answer are:\n\n\\- Is giving 1 drops\u002F 10kg\u002F times, twice daily for 8 weeks will change the level of LDL and HDL level in diabetic type 2 patients compared to placebo? Researchers will compare propolis to a placebo (a look-alike substance that contains no drug) to see if propolis works to change LDL and HDL cholesterol level.\n\nParticipants will:\n\n* Take propolis or a placebo, 2 times daily with given dose (1 drops\u002F10 kg\u002Ftimes) every day for 2 months\n* Visit the sub-district health centre once every 2 weeks for checkups\n* Get their blood checked before and after intervention",[525],"Diabetes Mellitus Type 2",[527,525,528,529],"Propolis","Low Density Lipoprotein","High Density Lipoprotein","2025-03-29",{"date":532,"type":40},"2025-04-03",{"date":534,"type":40},"2025-03-18",{"date":536,"type":21},"2025-07-31",{"name":46,"class":47},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":465,"minAge":299,"maxAge":167,"enrollmentInfo":545,"targetDuration":4,"studyType":22,"phases":547,"briefSummary":549,"conditions":550,"keywords":552,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":4},"100580619","phase-1-umbilical-cord-mesenchymal-stem-cell-secretome-in-severe-erectile-dysfunction-non-responsive-to-sildenafil-100580619","NCT06839651","Umbilical Cord Mesenchymal Stem Cell Secretome in Severe Erectile Dysfunction Non-responsive to Sildenafil","Analysis of the Safety and Efficacy of Administering Umbilical Cord Mesenchymal Stem Cell Secretome in Patients with Severe Erectile Dysfunction Non-responsive to Sildenafil","Inclusion Criteria:\n\n* Men aged 40-65 years who undergo treatment at the Andrology Clinic of RSUD Dr. Soetomo.\n* Severe erectile dysfunction caused by organic factors for at least 6 months, based on an IIEF-5 score of 5-7\n* History of undergoing treatment with sildenafil 100 mg for four sessions.\n* Evaluation of IIEF-5 score \\\u003C 22 and not meeting the MCID criteria, defined as an IIEF-5 score increase of less than 4\n* Type II Diabetes Melitus with an HbA1c test result of \\\u003C 7%.\n* Laboratory test results for liver function (SGOT and SGPT) and kidney function (urea and creatinine) are within normal limits.\n* Patients with undergoing treatment with antidepressant.\n\nExclusion Criteria:\n\n* Anatomical abnormalities of the penis that are clinically visible, such as Peyronie's disease, a history of priapism, a history of penile implants, skin irritation, and lesions in the area surrounding the penile skin.\n* Active and significant systemic or local infection.\n* History of bleeding or blood clotting disorder therapy.\n* History of systemic autoimmune disorders and immunosuppressive treatment\n* History of prostate surgery, history of malignancy, or a PSA level \\> 4 ng\u002FmL.\n* Untreated hypogonadism or low serum total testosterone (\\\u003C200 ng\u002FdL).\n* Uncontrolled hypertension or hypotension (systolic blood pressure \\>170 or \\\u003C90 mmHg, and diastolic blood pressure \\>100 or \\\u003C50 mmHg).\n* Unstable cardiovascular disease (e.g., unstable angina, myocardial infarction within the last 6 months, and congestive heart failure).",{"count":546,"type":21},10,[548],"PHASE1","The study is an experimental pre-post-test design involving 10 patients with severe ED non-responsive to sildenafil. Safety parameters included pain, hematoma, local bleeding, and infection, while efficacy was measured using the IIEF-5 questionnaire, EHS, and morning erection.",[551],"Erectile Dysfunctions",[553,554,555],"Erectile dysfunction","secretome","UC-MSC","2025-02-24",{"date":558,"type":40},"2025-02-25",{"date":560,"type":21},"2025-04-21",{"date":562,"type":21},"2026-04-01",{"name":46,"class":47},{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":570,"eligibilityCriteria":571,"healthyVolunteers":80,"sex":17,"minAge":572,"maxAge":196,"enrollmentInfo":573,"targetDuration":4,"studyType":22,"phases":575,"briefSummary":576,"conditions":577,"keywords":581,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":48},"100487125","dietary-modulation-of-gut-microbiota-in-overweightobese-adolescents-and-covid-19-infection-100487125","NCT05623007","Dietary Modulation of Gut Microbiota in Overweight\u002FObese Adolescents and COVID-19 Infection","Dietary Modulation of Gut Microbiota on Nutritional Status and COVID-19 Infection in Adolescents: Gut-Lung-Axis","DIVINE","Inclusion Criteria:\n\n1. living in Jakarta, Surabaya, and Yogyakarta City for at least 6 months permanently;\n2. apparently healthy;\n3. male and female, age 12-17 years old;\n4. overweight or obese (BMI-for-age z-score \\>+1SD);\n5. have completed at least two dosages of COVID-19 vaccine, the vaccine must be CoronaVac® (Sinovac);\n6. minimal 6 months post vaccinated prior to recruitments.\n7. parents willing to sign the informed consent and adolescents give informed assent;\n8. Must have an active health insurance, for instance BPJS or similar health insurance.\n\nExclusion Criteria:\n\n1. having a history of COVID-19 infection within the last month confirmed by PCR or antigen from health care facilities or independent laboratory;\n2. having a history of chronic and non-communicable diseases, congenital diseases, and disabilities;\n3. reported current diagnosed as suspected active Tuberculosis (primary lung TB, miliary TB, bleeding cough bone TB, meningitis TB);\n4. having a history of gastrointestinal or malabsorption disorder (such as celiac disease and inflammatory bowel disease) within the last three months or during the study;\n5. taking antibiotics during 2 weeks before the start of the study (adolescents will be included after 3 weeks of last antibiotic intake);\n6. taking other medications or having diseases that may influence the immune response - i.e. immune deficiencies, immunosuppressants medications, blood transfusion or other blood products;\n7. taking insulin and\u002For anti-dyslipidemia medication;\n8. being pregnant and\u002For breastfeeding.","12 Years",{"count":574,"type":21},440,[24],"Probiotic intervention has been currently suggested to provide supportive benefits in promoting health, including alleviating disease symptoms, protecting against diarrhea and respiratory infection, affecting growth and modulating the immune system by improving the beneficial gut microbiota colonization, giving direction on the gut-lung-axis pathway. This indicates that probiotics may become alternative to improve nutrition and reduce the risk of viral infections which may reduce the risk against Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2). Introduction to probiotics during adolescence can alleviate inflammation and invert dysbiosis. However, evidence on the effect of probiotic supplementation on enhancing antibody response to SARS COV-2 in adolescents is lacking. Moreover, previous studies showed the potential effect of probiotic supplementation to improve overweight and obesity in adolescents. A bi-directional relationship exists among nutrition, infection, and immunity as changes in one element will affect the others. The main objective of this study is to investigate the effect of dietary modulation of overweight and obese adolescent's gut microbiota through probiotic supplementation combined with healthy eating and physical activity counseling and psychosocial stimulation on nutritional status and antibody response to COVID-19 vaccination. This trial will conduct a 20-week intervention for overweight and obese adolescents.",[578,579,580],"Health Behavior","Child Development","Adolescent Obesity",[582,583,584,474,585],"adolescent","probiotics","COVID-19","obese","2025-02-23",{"date":558,"type":40},{"date":589,"type":40},"2022-11-01",{"date":591,"type":21},"2025-12-30",{"name":46,"class":47},{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":4,"eligibilityCriteria":599,"healthyVolunteers":80,"sex":17,"minAge":600,"maxAge":57,"enrollmentInfo":601,"targetDuration":4,"studyType":22,"phases":603,"briefSummary":604,"conditions":605,"keywords":608,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":624,"locationsCount":48},"100576079","the-effects-of-brown-rice-compared-to-white-rice-on-postprandial-changes-in-il-6-and-mda-levels-in-sedentary-workers-100576079","NCT06780618","The Effects of Brown Rice Compared to White Rice on Postprandial Changes in IL-6 and MDA Levels in Sedentary Workers","The Effects of Brown Rice Consumption Compared to White Rice on Postprandial Changes in Interleukin-6 and Malondialdehyde Levels in Sedentary Workers","Inclusion Criteria:\n\n* healthy administrative employees,\n* age 21-59 years,\n* normal body mass index (18.5-22.9 kg\u002Fm2),\n* low physical activity (≤600 METs minutes\u002Fweek),\n* assign for informed consent\n\nExclusion Criteria:\n\n* being pregnant\u002Fbreastfed\u002Fmenopause,\n* consumption of herbal medicines and\u002For supplements within 24 hours before data collection,\n* having history of DM, CVD, cancer, and autoimmune disease,\n* being vegan,\n* smoking\u002Falcohol drinking,\n* allergic to research food's ingredients","21 Years",{"count":602,"type":21},30,[24],"The goal of this clinical trial is to learn if brown rice and white rice affect oxidative stress and inflammation in office workers who don't exercise much. The main question it aims to answer is:\n\nDoes eating brown rice change MDA and IL-6 levels differently than eating white rice in people who don't exercise much?\n\nParticipants will:\n\nBe interviewed to collect personal data, medical history, lifestyle habits, and dietary patterns.\n\nBe measured to calculate Body Mass Index (BMI). Be interviewed to complete a questionnaire to assess their physical activity level in the past week.\n\nBe interviewed to record all food and beverages consumed in the past 24 hours. Blood samples will be drawn twice, before and after consuming the research meal.\n\nBe provided with a research meal consisting of rice (either brown or white), scrambled eggs, and tofu stew that must be finished within 15 to 20 minutes.",[606,607],"Sedentary Employees","Postprandial Oxidation and inflammation",[609,610,611,612,613,614,615,616],"brown rice","white rice","interleukin-6","malondialdehyde","sedentary","inflammation","oxidative stress","postprandial","2025-01-21",{"date":619,"type":40},"2025-01-24",{"date":621,"type":40},"2025-01-06",{"date":623,"type":21},"2025-04-30",{"name":46,"class":47},{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":4,"eligibilityCriteria":631,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":167,"enrollmentInfo":632,"targetDuration":4,"studyType":22,"phases":633,"briefSummary":634,"conditions":635,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":643,"locationsCount":48},"100576304","the-analgesia-effect-of-electroacupuncture-battlefield-acupuncture-versus-sham-electroakupuncture-post-surgery-100576304","NCT06783556","The Analgesia Effect of Electroacupuncture Battlefield Acupuncture Versus Sham Electroakupuncture Post Surgery","The Analgesia Effect of Electroacupuncture of Battlefield Acupuncture (BFA) Versus Sham Electroacupuncture on Pain, Analgesic Dose Reduction and Quality of Life Post Percutaneous Nephrolithotomy Surgery","Inclusion Criteria:\n\n* Men or women aged 18-65 years\n* Patients who have been diagnosed with kidney stones measuring \\> 2 cm and will undergo PCNL surgery\n* VAS score \\\u003C7, assessed 2 hours before PCNL surgery\n* Receive standard analgesic therapy\n* Willing to participate in this study until completion and sign an informed consent.\n\nExclusion Criteria:\n\n* Kidney anatomical abnormalities\n* Ear deformities (microtia)\n* Patients with cognitive impairment, uncooperative (receiving antidepressants or strong opioid or narcotic analgesics)\n* Tumors, wounds or skin infections in the needling area.\n* Heart rhythm disorder, unstable hemodynamics that require intensive care including extremely high body temperature and using a pacemaker.\n* Allergy to acupuncture needles or certain metals\n* Patients who have had a DJ stent or nephrostomy before PCNL\n* History of metal implants in the body except amalgam",{"count":602,"type":21},[24],"The goal of this clinical trial is to learn the effect of ear electroacupuncture BFA therapy in reducing pain, analgesic dose, and improving patient quality of live post percutaneous nephrolithotomy surgery. The main questions it aims to answer are:\n\n* Does BFA ear electroacupuncture reduce postoperative pain of percutaneous nephrolithotomy surgery better than sham electroacupuncture group?\n* Does BFA ear electroacupuncture reduce postoperative analgesic dose of percutaneous nephrolithotomy surgery better than sham electroacupuncture group?\n* Does BFA ear electroacupuncture improve postoperative quality of life of percutaneous nephrolithotomy surgery better than sham electroacupuncture group?\n\nResearchers will compare ear electroacupuncture BFA to sham electroacupuncture to see the different analgesia effect between these groups.\n\nParticipants will:\n\n* Get ear electroacupuncture BFA or sham electroacupuncture therapy, 2 hours before surgery for 30 minutes\n* Take drug paracetamol 1000 mg intravenous after surgery according to the needs of the patient's pain complaints after surgery in both groups",[636],"Percutaneous Nephrolithotomy","2025-01-18",{"date":639,"type":40},"2025-01-22",{"date":641,"type":21},"2025-01-20",{"date":480,"type":21},{"name":46,"class":47},""]